Compare NISN & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NISN | AIMD |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 16.9M |
| IPO Year | 2016 | N/A |
| Metric | NISN | AIMD |
|---|---|---|
| Price | $3.60 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 41.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $340,219,546.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | 8.05 | ★ 178.19 |
| 52 Week Low | $3.22 | $1.78 |
| 52 Week High | $9.33 | $5.00 |
| Indicator | NISN | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 33.46 |
| Support Level | $3.58 | $1.78 |
| Resistance Level | $3.82 | $2.27 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 0.00 | 23.19 |
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.